ScholarIQanswers from OpenAlex & ORCID
Aditya Bardia
ResearcherPublications, citations & collaboration network
Aditya Bardia is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Aditya Bardia have?
ScholarIQindexed works
Aditya Bardia has 1,143 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Aditya Bardia have?
ScholarIQcitation count
Aditya Bardia has 40,117 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Aditya Bardia?
ScholarIQh-index
Aditya Bardia has an h-index of 90 in OpenAlex.
What is the i10-index of Aditya Bardia?
ScholarIQi10-index
Aditya Bardia has an i10-index of 323 in OpenAlex.
What is the ORCID of Aditya Bardia?
ScholarIQorcid
The ORCID for Aditya Bardia is on the source record.
What is the OpenAlex record for Aditya Bardia?
ScholarIQopenalex
The OpenAlex for Aditya Bardia is on the source record.
What are the most-cited papers on Aditya Bardia?
ScholarIQmost cited works
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Min Yu, Aditya Bardia, Ben S. Wittner, Shannon L. Stott, Malgorzata E. Smas, David T. Ting, Steven J. Isakoff, Jordan C. Ciciliano, Marissa Wells, Ajay M. Shah, Kyle Concannon, Maria Donaldson Collier, Lecia V. Sequist, Elena F. Brachtel, Dennis C. Sgroi, José Baselga, Sridhar Ramaswamy, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera, Sanjay Shete, Chih–Yuan Hsu, Aakash Desai, Gilberto Lopes, Petros Grivas, Corrie Painter, Solange Peters, Michael A Thompson, Ziad Bakouny, Gerald Batist, Tanios Bekaii‐Saab, Mehmet Asım Bilen, Nathaniel Bouganim, Mateo Bover Larroya, Daniel Castellano, Salvatore A. Del Prete, Deborah B. Doroshow, Pamela Egan, Arielle Elkrief, Dimitrios Farmakiotis, Daniel Flora, Matthew D. Galsky, Michael Glover, Elizabeth A. Griffiths, Anthony P. Gulati, Shilpa Gupta, Navid Hafez, Þorvarður R. Hálfdánarson, Jessica E. Hawley, Emily Hsu, Anup Kasi, Ali Raza Khaki, Christopher A. Lemmon, Colleen Lewis, Barbara Logan, Tyler Masters, Rana R. McKay, Ruben A. Mesa, Alicia K. Morgans, Mary F. Mulcahy, Orestis A. Panagiotou, Prakash Peddi, Nathan A. Pennell, Kerry L. Reynolds, L Rosen, Rachel Rosovsky, Mary Salazar, Andrew Schmidt, Sumit Shah, Justin Shaya, John A. Steinharter, Keith Stockerl‐Goldstein, Suki Subbiah, Donald C. Vinh, Firas Wehbe, Lisa B. Weissmann, Julie Wu, Elizabeth Wulff‐Burchfield, Zhuoer Xie, Albert C. Yeh, Peter Paul Yu, Alice Y. Zhou, Leyre Zubiri, Sanjay Mishra, Gary H. Lyman, Brian I. Rini, Jeremy L. Warner, Maheen Z. Abidi, Jared D. Acoba, Neeraj Agarwal, Syed A. Ahmad, Archana Ajmera, Jessica K. Altman, Anne H. Angevine, Nilo Azad, Michael Bär, Aditya Bardia, Jill S. Barnholtz‐Sloan, Briana Barrow, Babar Bashir, Rimma Belenkaya, Stephanie Berg, Eric Bernicker, Christine M. Bestvina, Rohit Bishnoi, Genevieve M. Boland, Mark Bonnen, Gabrielle Bouchard, Daniel W. Bowles, Fiona Busser, Angelo Cabal, Paolo F. Caimi, Theresa M. Carducci, Carla Casulo
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah A. Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie‐Ange Mouret‐Reynier, Joohyuk Sohn, Donatienne Taylor, Kathleen Harnden, Hung T. Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, José Á. García-Sáenz, Emilio Bria, Marina Elena Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortés, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia